Olema Pharmaceuticals, Inc.
OLMAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeOlema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The $961.2M market capitalization puts OLMA squarely in small-cap range for its industry. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.
Market Cap
$961.2M
Beta
1.99
P/E (TTM)
—
P/E (Fwd)
-4.09
EPS (TTM)
$-2.12
EPS (Fwd)
$-2.69
ROE
-52.7%
ROA
-31.8%
Cash
$461.1M
Total Debt
$3.7M
Free CF
-$89.1M
52W Change
37.6%
Annual Financials
Cash vs Debt
Where OLMA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, OLMA finished 26.92% below its 150-day moving average ($14.82) and 38.88% below its 200-day moving average ($17.72). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OLMA overbought or oversold?
At the September 3, 2026 close, OLMA's RSI(14) was 54.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $461.1M in cash comfortably exceeding the $3.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$89.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -52.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta above 1.5, OLMA tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, OLMA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing OLMA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.